Steiner H, Gerfen C R
Department of Anatomy and Neurobiology, University of Tennessee, College of Medicine, Memphis 38163, USA.
Neuroscience. 1999;88(3):795-810. doi: 10.1016/s0306-4522(98)00241-3.
Projection neurons of the striatum release opioid peptides in addition to GABA. Our previous studies showed that the opioid peptide dynorphin regulates that subtype of projection neurons which sends axons to the substantia nigra/entopeduncular nucleus, as indicated by an inhibitory action of dynorphin/agonists on D1 dopamine receptor-mediated immediate-early gene induction in these neurons. The other subtype of striatal projection neurons projects to the globus pallidus and contains the opioid peptide enkephalin. Here, we investigated whether enkephalin regulates the function of striatopallidal neurons, by analysing opioid effects on immediate-early gene induction by D2 dopamine receptor blockade that occurs in these neurons. Thus, the effects of systemic and intrastriatal administration of various opioid receptor agonists and antagonists on immediate-early gene expression (c-fos, zif 268) induced by the D2 receptor antagonist eticlopride were examined with in situ hybridization histochemistry. Intrastriatal infusion of enkephalin (delta and mu), but not dynorphin (kappa), receptor agonists suppressed immediate-early gene induction by eticlopride in a dose-dependent manner. This suppression was blocked by the opioid receptor antagonist naloxone, confirming the involvement of opioid receptors. Repeated treatment with D2 receptor antagonists produces increased enkephalin expression and diminished immediate-early gene inducibility in striatopallidal neurons, as well as behavioral effects that are attenuated compared to those of acute treatment (e.g., reduced akinesia). Naloxone reversed such behavioral recovery (i.e. reinstated akinesia), but did not significantly affect suppressed immediate-early gene induction. Our results indicate that enkephalin acts, via mu and delta receptors in the striatum, to inhibit acute effects of D2 receptor blockade in striatopallidal neurons. Moreover, the present findings suggest that increased enkephalin expression after repeated D2 receptor antagonist treatment is an adaptive response that counteracts functional consequences of D2 receptor blockade, but is not involved in suppressed immediate-early gene induction. Together with our earlier findings of the role of dynorphin, these results indicate that opioid peptides in the striatum serve as negative feedback systems to regulate the striatal output pathways in which they are expressed.
纹状体的投射神经元除释放γ-氨基丁酸(GABA)外,还释放阿片肽。我们之前的研究表明,阿片肽强啡肽调节将轴突发送至黑质/脚内核的投射神经元亚型,强啡肽/激动剂对这些神经元中D1多巴胺受体介导的即刻早期基因诱导具有抑制作用,这表明了上述调节作用。纹状体投射神经元的另一个亚型投射至苍白球,并含有阿片肽脑啡肽。在此,我们通过分析阿片类物质对这些神经元中因D2多巴胺受体阻断而发生的即刻早期基因诱导的影响,来研究脑啡肽是否调节纹状体苍白球神经元的功能。因此,利用原位杂交组织化学技术,检测了全身及纹状体内注射各种阿片受体激动剂和拮抗剂对由D2受体拮抗剂依替必利诱导的即刻早期基因表达(c-fos、zif 268)的影响。纹状体内注入脑啡肽(δ和μ)受体激动剂,而非强啡肽(κ)受体激动剂,可剂量依赖性地抑制依替必利诱导的即刻早期基因表达。阿片受体拮抗剂纳洛酮可阻断这种抑制作用,证实了阿片受体的参与。重复给予D2受体拮抗剂会使纹状体苍白球神经元中脑啡肽表达增加,即刻早期基因诱导能力减弱,以及产生与急性给药相比减弱的行为效应(如运动不能减轻)。纳洛酮可逆转这种行为恢复(即恢复运动不能),但对被抑制的即刻早期基因诱导没有显著影响。我们的结果表明,脑啡肽通过纹状体中的μ和δ受体发挥作用,抑制纹状体苍白球神经元中D2受体阻断的急性效应。此外,目前的研究结果表明,重复给予D2受体拮抗剂后脑啡肽表达增加是一种适应性反应,可抵消D2受体阻断的功能后果,但不参与被抑制的即刻早期基因诱导。与我们之前关于强啡肽作用的研究结果一起,这些结果表明纹状体中的阿片肽作为负反馈系统来调节它们所表达的纹状体输出通路。